Lixivaptan: A novel vasopressin receptor antagonist

Expert Opinion on Investigational Drugs

Volumn 18, Issue 5, 2009, Pages 657-662

  Ku, Elaine ^a   Nobakht, Niloofar ^a   Campese, Vito M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antidiuretic hormone; Hyponatremia; Lixivaptan; Vasopressin; Vasopressin receptor antagonist

Indexed keywords

CONIVAPTAN; LIXIVAPTAN; M 0002; MOZAVAPTAN; RWJ 351647; SODIUM; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ASCITES; BRADYCARDIA; CONGESTIVE HEART FAILURE; DEHYDRATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; HUMAN; HYPERNATREMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY POLYCYSTIC DISEASE; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; TACHYCARDIA; THIRST; VASOPRESSIN BLOOD LEVEL;

ANIMALS; AZEPINES; BENZAMIDES; CLINICAL TRIALS, PHASE III AS TOPIC; HEART FAILURE; HUMANS; KIDNEY DISEASES; RECEPTORS, VASOPRESSIN;

EID: 67649622339     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902889760     Document Type: Review

References (45)

1. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(Suppl 1):S1-21
2. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-858 (Pubitemid 46607386)
3. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-390 (Pubitemid 32718586)
4. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-1632 (Pubitemid 351626846)
5. Lolait SJ, O'Carroll AM, Mahan LC, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 1995;92:6783-6787
6. Fushimi K, Uchida S, Hara Y, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361:549-552
7. Umenishi F, Narikiyo T, Vandewalle A, Schrier RW. cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-independent pathway. Biochim Biophys Acta 2006;1758:1100-1105 (Pubitemid 44373864)
8. Gines P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851-864
9. Ghali JK. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology 2008;111:147-157
10. Plum J, Mirzaian Y, Grabensee B. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome. Nephrol Dial Transplant 1996;11:1034-1042 (Pubitemid 26182495)
11. Schrier RW, Cadnapaphornchai MA, Ohara M. Water retention and aquaporins in heart failure, liver disease and pregnancy. J R Soc Med 2001;94:265-269 (Pubitemid 32588180)
12. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988;319:1065-1072 (Pubitemid 18247994)
13. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-2072
14. Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884-1890 (Pubitemid 40627814)
15. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Effect Resour Alloc 2006;4:10 (Pubitemid 44151615)
16. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337:169-172 (Pubitemid 37329815)
17. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(Suppl 1):S30-5
18. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996;156:1814-1820 (Pubitemid 26295226)
19. Farmakis D, Filippatos G, Parissis J, et al. Hyponatremia in heart failure. Heart Fail Rev 2009;14:59-63
20. Rossi J, Bayram M, Udelson JE, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007;9:82-86
21. Cardenas A, Gines P. Predicting mortality in cirrhosis - serum sodium helps. N Engl J Med 2008;359:1060-1062
22. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006;69:2124-2130 (Pubitemid 43882098)
23. Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653-2659 (Pubitemid 24006529)
24. Gross P. Treatment of hyponatremia. Intern Med 2008;47:885-891 (Pubitemid 351936183)
25. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112 (Pubitemid 44749318)
26. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971
27. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331
28. Albright JD, Reich MF, Delos Santos EG, et al. 5-Fluoro-2-methyl-N-[4- (5H-pyrrolo [2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl] benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998;41:2442-2444
29. Chan PS, Coupet J, Park HC, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998;449:439-443
30. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008;118:410-421
31. Martinez-Castelao A. Lixivaptan (American Home Products). Curr Opin Investig Drugs 2001;2:525-530
32. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36:1197-1205 (Pubitemid 35253436)
33. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939
34. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182-191 (Pubitemid 36042159)
35. Kumar S, Rubin S, Mather PJ, Whellan DJ. Hyponatremia and vasopressin antagonism in congestive heart failure. Clin Cardiol 2007;30:546-551 (Pubitemid 350209965)
36. Abraham WT, Shamshirsaz AA, McFann K, et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-1621
37. Biogen Idek and Cardiokine Partner to Develop Lixivaptan, a Novel Vasopressin Antagonist. 2007. Available from: http://www.reuters.com/article/ pressRelease/idUS162428+14-Feb-2008+BW20080214 [last accessed 6 April 2009]
38. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001;138:18-21 (Pubitemid 32589198)
39. Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:102-108
40. Gattone VH 2nd. Emerging therapies for polycystic kidney disease. Curr Opin Pharmacol 2005;5:535-542
41. Belibi FA, Reif G, Wallace DP, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004;66:964-973
42. Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000;57:1460-1471 (Pubitemid 30207906)
43. Torres VE. Vasopressin antagonists in polycystic kidney disease. Semin Nephrol 2008;28:306-317 (Pubitemid 351749754)
44. Shimizu K. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Kidney Int 1995;48:220-226
45. Steiner M, Phillips MI. Renal tubular vasopressin receptors downregulated by dehydration. Am J Physiol 1988;254:C404-10 (Pubitemid 18093179)